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Abstract
Cystic ﬁbrosis (CF) centres can assess the quality of the care they deliver by benchmarking their practices and outcomes against those
of other CF centres. This is most easily done using summaries of electronic patient records, such as are generated by patient registries. All
centres should assess their compliance with standards of care, as determined by consensus documents and evidence-based medicine, and
continually seek out and implement ways to improve their clinical outcomes. This may imply changes to routine centre practice as well as to
treatment strategies.
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1. Introduction
From the youngest age, cystic ﬁbrosis (CF) patients depend
on their care givers to mount a team effort that offers them the
longest life expectancy and best possible quality of life. The
topic of this presentation is how to identify and implement
best practices in CF care.
2. Benchmarking
Benchmarking is a term used to describe the evaluation
of one’s own performance in comparison to someone else’s,
according to speciﬁed standards, in order to improve one’s
performance. It implies the search for those best practices that
are associated with superior outcomes as well as discovering
new methods, ideas and tools to improve effectiveness, and
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paying attention to the subtleties of care, in other words
“stealing good ideas shamelessly”. Many parameters can
be benchmarked, including body mass index, percentage of
patients on standard of care, lung function determinants, CT
score, quality of life and percentage of patients chronically
infected with Pseudomonas aeruginosa among many others.
Selected indicators can be used to evaluate performance
within a single centre on a year-to-year basis as well as
for centre-to-centre comparisons [1]. Especially for the latter,
correction for various confounders such as genotype, age
distribution and socio-economic class is needed.
3. Requirements for an effective CF centre
The CF team should be coordinated by a CF centre
director. The core CF team consists of a lung physician,
gastroenterologist, specialized nurse(s), physiotherapist(s), di-
etician, social worker, psychologist, clinical pharmacist and
clinical microbiologist. Other specialists with expertise in CF
should be close at hand such as a geneticist, abdominal /
thoracic surgeon, and gynaecologist. Ideally a centre should
consist of a paediatric and an adult unit working closely
together to facilitate seamless transition and to support the
critical mass of the CF team. A European consensus on
standards of care has been published [2].
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In order to maintain sufﬁcient expertise, each centre should
care for a minimum of 50 CF children or adults [2]. There are
many reasons why centralized care in clinics of sufﬁcient size
is important. Firstly, CF care requires a complete CF team
whose members must invest a great deal of time in continuing
education and must innovate care to the highest possible level.
Scientiﬁc developments are occurring at an ever faster pace;
patients are well informed about these developments and
rightly require that the care they receive meet international
standards. Secondly, the infrastructure required to provide
the best of care to CF patients is becoming more and more
costly. This infrastructure must include in- and out-patient
facilities that permit appropriate infection control, access to
lung function and CF microbiology laboratories and imaging
facilities, as well as on-line access to all diagnostic data and
to its own electronic database of CF patient records. Further-
more, it must be able to provide education to CF patients and
their families and should participate in properly conducted,
preferably international, clinical research. Financial commit-
ment from hospital management is mandatory to maintain
the infrastructure and the complete multidisciplinary team of
essential CF specialists at the appropriate level. Thirdly, it
is well recognized that a large enough number of patients is
important in generating and maintaining adequate expertise in
the complicated disease that CF is.
Despite the consensus that the minimal size for a centre is
50 CF patients, it is surprising that in many countries patients
are still being cared for in smaller centres [1]. Hence, further
centralization of CF care should be considered an important
opportunity to enhance care in a cost-efﬁcient way
4. Facilities at the Sophia Children’s Hospital
Our clinic at the Erasmus Medical Centre – Sophia Chil-
dren’s Hospital, where 150 children with CF are treated, is
dedicated to optimizing care for CF patients and provides
access to the facilities listed in Table 1. An electronic pa-
tient record is essential for easy and complete access to key
data. It permits review of the patient’s history within a few
Table 1
Facilities available to the CF centre at Erasmus MC – Sophia Children’s
Hospital (date of introduction)
CF Electronic Patient Record (2006)
CFQ quality of life questionnaire (2007)
– Automated patient education (2008)
– Access of patient to patient record (2008)
Flexible bronchoscopy (1992): 2 slots/week
Lung function
– Infant pulmonary function measurements (1993)
– Multiple-breath washout (2006)
Computed tomography (CT) (1996): 2 ﬁxed slots/week
– Controlled-volume CT (2007)
Magnetic resonance imaging (2006): 1 ﬁxed slot/week
Cystic ﬁbrosis transmembrane conductance regulator (CFTR) functional
tests
– Intestinal current measurements (ICM) (1987): 1 ﬁxed slot/week
– Nasal potential difference (NPD) (2002): 1 ﬁxed slot/week
minutes before the patient enters the examination room. The
physician can efﬁciently and completely evaluate all relevant
complexities of the patient’s clinical care, including longi-
tudinal trends from graphic display of important indicators
such as Body Mass Index (BMI) or lung function parameters
such as the forced expiratory volume in one second (FEV1).
Hence, the risk of overlooking relevant information is reduced
and unnecessary questions to the patient can be avoided.
The graphic display of key indicators can be shown to the
patient to explain certain treatment decisions or to encourage
adherence to therapy. Our electronic record is also set up to
provide patient education materials automatically as required.
Furthermore, it structures care because it forces the clinician
to use standardized forms for clinical follow-up visits and to
schedule, for example, the routine annual check-up using an
electronic form where mandatory and optional items are listed
separately. Port-CF, the web-based data collection vehicle of
the US Cystic Fibrosis Foundation Patient Register (CFFPR,
http://www.cff.org/CCNP/Register/) that will be used in the
near future by many European CF centres, offers similar
advantages. Like other registries, it also allows compilation
of anonymised data from many centres into comprehensive
reports that aid in the clinical management of CF.
5. Optimising routine centre practices
Analysis of multi-centre data compiled into patient reg-
istries provides many clues about the most successful current
practices. For example, a recent presentation from the CFFPR
reported that teenagers were more likely than other CF pa-
tients to lose >5% of their lung function per year [3]. A
pertinent previous analysis, performed by the Epidemiologic
Study of Cystic Fibrosis (ESCF), found that the CF centres
with the best outcomes in terms of FEV1 performed more
frequent spirometry and sputum cultures and prescribed more
frequent and longer courses of intravenous antibiotics than
other centres, particularly in teenagers with only mild to mod-
erate lung function impairment [4]. Thus, it seems particularly
important for optimum health to detect and treat acute lung
infections in adolescents. Furthermore, Boyle pointed out that,
although very few young patients are seen only once or twice
per year, the proportion rises to over 30% in patients over 18
years of age, suggesting that older patients may need to be
seen more frequently, starting in the teenage years [3].
6. Optimising treatment strategies
Medical treatments should be evidence-based and, while
there have been few controlled clinical trials in the past, their
number is increasing even if the median sample size is still
too small [5]. The power of trials to answer important clinical
questions can be improved only by establishing clinical trial
networks [6]. Despite this recent progress in the science of
CF care, individual CF centres are still inconsistent in their
implementation of evidence-based therapies. For example, a
consortium of six CF centres in the United States compared
their therapeutic strategies and found that the percentage
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Fig. 1. Reasons physicians do not prescribe dornase alfa [7]. Data from the
NNECFC clinic encounter forms 2002–2005, reproduced with permission.
Fig. 2. Reasons physicians do not prescribe aerosolised tobramycin [7].
Data from the NNECFC clinic encounter forms 2002–2005, reproduced with
permission.
of eligible patients who received evidence-based treatment
ranged from 20% to 75% for dornase alfa and from 40 to
90% for inhaled tobramycin [7]. The reason given for most of
the patients not receiving these treatments was that they were
perceived as well (Figs. 1 and 2). This is a striking ﬁnding
since the intention of these therapies is primarily to prevent
Fig. 3. Use of dornase alfa in patients older than 6 years of age and with
FEV1 below 90% predicted in the six CF centres of the Northern New
England CF Consortium 1998–2004 [7], reproduced with permission.
Fig. 4. Use of aerosolized tobramycin in patients over 6 years old with
cultures positive for P. aeruginosa in the six CF centres of the Northern New
England CF Consortium 1998–2004 [7], reproduced with permission.
deterioration in order to maintain lung health [8]. After the
centres in the consortium had agreed on how the therapies
should be prescribed and had instituted a quality improvement
program, the use of both treatments became less variable and
exceeded the national average (Figs. 3 and 4).
7. Summary
The key to improving quality of care in any CF centre
is the care team’s eagerness to improve care. Visits to other
centres offer an opportunity to learn and to “steal good
ideas shamelessly”. CF centres should manage a minimum
of 50 patients in order to hone their expertise. Electronic
patient records are a powerful tool to optimize patient care.
The attitude of CF teams should be to refuse any loss in
lung function, especially during puberty, by the consistent
implementation of evidence-based medicine. Adjusting care
to the highest standards and measuring its impact on outcomes
should be a key goal of every CF team.
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